RATIONALE: The Loudness Dependence of the Auditory Evoked Potential (LDAEP) has been suggested as a reliable measure of central serotonin function in humans; however, its specificity for the serotonin system remains a topic of debate, with possible modulation of this purported serotonin marker by other neurotransmitters, including dopamine. OBJECTIVES: We examined the effect of dopaminergic modulation on the LDAEP using the D1/D2/D3 dopamine receptor agonist pergolide and the D2/D3 agonist bromocriptine. METHODS: The study was a double-blind, placebo-controlled repeated-measures design in which healthy participants were tested under three acute treatment conditions: placebo, bromocriptine (2.5 mg), and pergolide (0.1 mg). Changes in the amplitude of the N1/P2 at intensities (60, 70, 80, 90, and 100 dB) were examined at C Z. RESULTS: Acute stimulation of D1/D2/D3 receptors with pergolide and D2/D3 receptors with bromocriptine in comparison with placebo had no effect on the LDAEP. CONCLUSION: These findings indicate that acute stimulation of dopamine D1, D2, and D3 receptors does not modulate the LDAEP in humans. Although the findings suggest that the LDAEP may not be modulated by acute changes in dopamine neurotransmission, further studies are needed to fully characterize its dopaminergic sensitivity.
RCT Entities:
RATIONALE: The Loudness Dependence of the Auditory Evoked Potential (LDAEP) has been suggested as a reliable measure of central serotonin function in humans; however, its specificity for the serotonin system remains a topic of debate, with possible modulation of this purported serotonin marker by other neurotransmitters, including dopamine. OBJECTIVES: We examined the effect of dopaminergic modulation on the LDAEP using the D1/D2/D3 dopamine receptor agonist pergolide and the D2/D3 agonist bromocriptine. METHODS: The study was a double-blind, placebo-controlled repeated-measures design in which healthy participants were tested under three acute treatment conditions: placebo, bromocriptine (2.5 mg), and pergolide (0.1 mg). Changes in the amplitude of the N1/P2 at intensities (60, 70, 80, 90, and 100 dB) were examined at C Z. RESULTS: Acute stimulation of D1/D2/D3 receptors with pergolide and D2/D3 receptors with bromocriptine in comparison with placebo had no effect on the LDAEP. CONCLUSION: These findings indicate that acute stimulation of dopamine D1, D2, and D3 receptors does not modulate the LDAEP in humans. Although the findings suggest that the LDAEP may not be modulated by acute changes in dopamine neurotransmission, further studies are needed to fully characterize its dopaminergic sensitivity.
Authors: Jürgen Gallinat; Daniel Senkowski; Catrin Wernicke; Georg Juckel; Isabell Becker; Thomas Sander; Michael Smolka; Ulrich Hegerl; Hans Rommelspacher; Georg Winterer; Werner M Herrmann Journal: Neuropsychopharmacology Date: 2002-07-25 Impact factor: 7.853
Authors: Georg Juckel; Jürgen Gallinat; Michael Riedel; Safet Sokullu; Carl Schulz; Hans-Jürgen Möller; Norbert Müller; Ulrich Hegerl Journal: Schizophr Res Date: 2003-11-15 Impact factor: 4.939
Authors: I Hui Lee; Yen Kuang Yang; Po See Chen; Hui Chun Huang; Tzung Lieh Yeh; Ru-Band Lu; Nan-Tsing Chiu; Wei Jen Yao; Shih-Hsien Lin Journal: Psychopharmacology (Berl) Date: 2010-11-12 Impact factor: 4.530
Authors: Kim De Keyser; Miet De Letter; Patrick Santens; Durk Talsma; Dick Botteldooren; Annelies Bockstael Journal: J Neural Transm (Vienna) Date: 2021-01-30 Impact factor: 3.575
Authors: Barry V O'Neill; Rodney J Croft; Sumie Leung; Chris Oliver; K Luan Phan; Pradeep J Nathan Journal: Psychopharmacology (Berl) Date: 2007-07-24 Impact factor: 4.530